References

Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J.
Ann Intern Med. 2011 Jun 21;154(12):797-805, W-292-3.
Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
Neurohr C, Hoffmann AL, Huppmann P, Herrera VA, Ihle F, Leuschner S, von Wulffen W, Meis T, Baezner C, Leuchte H, Baumgartner R, Zimmermann G, Behr J.
Respir Res. 2011 May 21;12:66.
Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial
D. Mark Davies, Petrus J. de Vries, Simon R. Johnson, Deborah L. McCartney, Jane A. Cox, Andreas L. Serra, Peter C. Watson, Christopher J. Howe, Tim Doyle, Kate Pointon, Justin J. Cross, Anne E. Tattersfield, J. Chris Kingswood, and Julian R. Sampson.
Clin Cancer Res 2011 April 27
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis.
McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee H-S, Krischer JP, Trapnell BC, for the National Institutes of Health Rare Lung Diseases Consortium and the MILES Trial Group.
N Engl J Med. 2011 Mar 16.
Lymphangioleiomyomatosis: a disease involving the lymphatic system.
Seyama K, Kumasaka T, Kurihara M, Mitani K, Sato T.
Lymphat Res Biol. 2010 Mar;8(1):21-31. Review.
Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis.
Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, Kwiatkowski D.
Mol Cancer. 2009 Jun 15; 8: 38.
Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene.
Pacheco-Rodriguez G, Kumaki F, Steagall WK, Zhang Y, Ikeda Y, Lin JP, Billings EM, Moss J.
J Immunol. 2009 Feb 1, 182(3):1270-7.
Clinical trials for rare lung diseases: lessons from lymphangioleiomyomatosis.
Kinder B, McCormack FX.
Lymphat Res Biol. 2010 Mar;8(1):71-9.
Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.
Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J.
Chest. 2009 May, 135(5): 1293-300.
Why and how do tumors stimulate lymphangiogenesis?
Cao Y.
Lymphat Res Biol. 2008;6(3-4):145-8. Review.
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN.
N Engl J Med. 2008 Jan 10; 358(2): 140-51.
TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis.
Pacheco-Rodriguez G, Steagall WK, Crooks DM, Stevens LA, Hashimoto H, Li S, Wang JA, Darling TN, Moss J.
Cancer Res. 2007 Nov 1, 67(21): 10573-81.